Status:

COMPLETED

A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome

Lead Sponsor:

University of Minnesota

Collaborating Sponsors:

University of Utah

Conditions:

Alport Syndrome

Kidney Disease

Eligibility:

MALE

Up to 18 years

Brief Summary

The goal of the Microalbuminuria in Untreated Boys with Alport Syndrome study is to gather information about critical clinical time points such as when patients with small amounts of protein (microalb...

Detailed Description

Study Aims 1. To determine the average ages of onset of microalbuminuria and overt proteinuria in untreated boys with Alport syndrome 2. To determine the average duration of microalbuminuria before t...

Eligibility Criteria

Inclusion

  • Diagnosis of Alport syndrome, confirmed by skin biopsy, kidney biopsy, or molecular genetic analysis
  • Diagnosis of Alport syndrome, based on presence of hematuria and confirmed diagnosis of Alport syndrome in a first-degree relative
  • Male gender
  • Absence of overt proteinuria, defined as urine protein:creatinine ratio less than 0.2 mg/mg
  • Subject is not currently receiving treatment with an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)

Exclusion

  • Female gender
  • Presence of overt proteinuria
  • Current treatment with ACEI or ARB
  • End-stage kidney disease (on dialysis or kidney transplant recipient)

Key Trial Info

Start Date :

July 1 2007

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

July 1 2012

Estimated Enrollment :

44 Patients enrolled

Trial Details

Trial ID

NCT00622544

Start Date

July 1 2007

End Date

July 1 2012

Last Update

July 20 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Minnesota

Minneapolis, Minnesota, United States, 55455